...
首页> 外文期刊>Scandinavian journal of immunology. >Suppressed expression of homotypic multinucleation, extracellular domains of CD172α (SIRP-α) and CD47 (IAP) receptors in TAMs upregulated by Hsp70-peptide complex in Dalton's lymphoma
【24h】

Suppressed expression of homotypic multinucleation, extracellular domains of CD172α (SIRP-α) and CD47 (IAP) receptors in TAMs upregulated by Hsp70-peptide complex in Dalton's lymphoma

机译:在道尔顿淋巴瘤中,Hsp70-肽复合物上调的TAM中同型多核化,CD172α(SIRP-α)和CD47(IAP)受体的胞外域表达受到抑制

获取原文
获取原文并翻译 | 示例

摘要

CD172α and CD47 are members of glycoprotein expressed on macrophages and various immune cells, promote immune recognition and T cell stimulation that priming phagocytosis of pathogens and apoptotic bodies and malignant cell. Tumour-releasing immunosuppressive factor promotes tumour growth and transforms the tumour resident M1 phenotype of macrophage to M2 phenotype (TAMs) that promotes tumour progression by downregulating the expression of different surface receptor including CD172α and CD47. Recent studies have reported that CD172α and CD47 are involved in the pathogenesis and promote malignancies such as lymphoma, leukaemia, melanoma, lung cancer and multiple myeloma, and their expression varies during infection and malignancies. Autologous Hsp70 is well recognized for its role in activating macrophages leading to enhance production of inflammatory cytokines. It has been observed that Hsp70 derived from normal tissues do not elicit tumour immunity, while Hsp70 preparation from tumour cell was able to elicit tumour immunity. However, the role of exogenous autologous hsp70 on the formation of giant cells is completely unknown. Therefore, in the present study, we sought to investigate the effect of Hsp70-peptide complex on the expression of CD172α and CD47 receptors in normal peritoneal macrophages (NMO) and TAMs. Finding shows that the expression of CD172α and CD47 enhances in TAMs and it reverts back the suppressed function of TAMs into M1 state of immunoregulatory phenotype that promotes tumour regression by enhanced multinucleation and phagocytosis of malignant cells and significantly enhances the homotypic fusion of macrophages and polykaryon formation in vitro by enhancing the expression of SIRPα and IAP.
机译:CD172α和CD47是在巨噬细胞和各种免疫细胞上表达的糖蛋白的成员,促进免疫识别和T细胞刺激,从而引发病原体和凋亡小体和恶性细胞的吞噬作用。释放肿瘤的免疫抑制因子促进肿瘤生长,并将巨噬细胞的驻留于肿瘤的M1表型转变为M2表型(TAM),该表型通过下调CD172α和CD47等不同表面受体的表达而促进肿瘤进展。最近的研究报道CD172α和CD47参与发病机理并促进恶性肿瘤,如淋巴瘤,白血病,黑色素瘤,肺癌和多发性骨髓瘤,它们的表达在感染和恶性肿瘤期间会发生变化。自体Hsp70因其在激活巨噬细胞中导致炎性细胞因子产生的作用而广为人知。已经观察到,来自正常组织的Hsp70不能引起肿瘤免疫,而从肿瘤细胞制备的Hsp70却能够引起肿瘤免疫。但是,外源自体hsp70在巨细胞形成中的作用是完全未知的。因此,在本研究中,我们试图研究Hsp70肽复合物对正常腹膜巨噬细胞(NMO)和TAM中CD172α和CD47受体表达的影响。研究结果表明,CD172α和CD47的表达在TAM中增强,并且将TAM的抑制功能恢复为M1状态的免疫调节表型,通过增强恶性细胞的多核化和吞噬作用促进肿瘤消退,并显着增强巨噬细胞的同型融合和多核形成在体外通过增强SIRPα和IAP的表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号